Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

Dyslipidemia Clinical Trial

Official title:

A 16-Week, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Extended Release Niacin/Laropiprant in South and Southeast Asians Not on a Lipid Modulating Agent, With Decreased High-Density Lipoprotein Cholesterol and Low- Density Lipoprotein Cholesterol at or Below NCEP ATP III Goal

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01414166
• Other study ID #: 0524A-108
• Secondary ID: CTRI/2012/08/002
• Status: Terminated
• Phase: Phase 3
• First received: August 9, 2011
• Last updated: April 27, 2015
• Start date: September 2011
• Est. completion date: February 2013

Study information

• Verified date: April 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: India: Drugs Controller General of India
• Study type: Interventional

Clinical Trial Summary

The study will evaluate the use of extended release niacin/laropiprant (ERN/LRPT) combination tablets in a primary prevention population currently not taking or eligible for lipid-modifying therapy (LMT); the population will comprise participants with low to moderate risk for coronary heart disease (CHD), low high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) at or below goal level, and normal or mildly elevated triglyceride (TG) levels.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 244
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• LMT ineligible

• Participants must meet the lipid criteria of "low to moderate CHD risk" as defined by National Cholesterol Education Program Adult Treatment Panel III Framingham Point Scores (NCEP ATP III)

• HDL-C <40 mg/dL (1.03 mmol/L) in males and <50 mg/dL (1.29 mmol/L) in females

• Triglyceride (TG) level <300 mg/dL (3.39 mmol/L).

• Fasting serum glucose (FSG) at Visit 1 AND Visit 2 <126 mg/dL (<7 mmol/L)

• Hemoglobin A1c (HbA1c) level <6.5%

• Participant willing to use acceptable method of contraception during the study, including the 14-day follow-up period

Exclusion criteria:

• History of malignancy =5 years prior to signing informed consent, except for adequately-treated basal cell or squamous cell skin cancer or in situ cervical cancer

• Participation in a study with an investigational compound (non-lipid-modifying) within 30 days

• Pregnant, breastfeeding, or expecting to conceive, or father a child during the study, including the 14-day follow-up period

• Consumption of more than 3 alcoholic drinks on any given day or more than 14 drinks per week

• Engages in or plans to engage in vigorous exercise or an aggressive diet regimen during the study

• Diabetes mellitus, based on medical history, FSG =126 mg/dL (7 mmol/L), and HbA1c =6.5%

• Risk factors for coronary heart disease

• Active or chronic hepatobiliary or hepatic disease

• Active peptic ulcer disease within 3 months of Visit 1

• History of hypersensitivity or allergic reaction to niacin or niacin-containing products

• Episode of gout within 1 year of Visit 1, unless currently stable on allopurinol

• Taking an LMT (including statins, bile acid sequestrants, fibrates and niacin >50 mg as monotherapy or coadministered with other LMTs)

• Use of over-the- counter or traditional medicine (e.g. red yeast rice products) for lipid-lowering

• Receiving treatment with systemic corticosteroids (unless on stable therapy for at lest 6 weeks for replacement for pituitary/adrenal/hypogonadal disease)

• Uncontrolled illness or infection

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias

Intervention

Drug:
• ERN/LRPT
ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
• placebo
ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Averaged Across Week 12 and Week 16	The percentage change from baseline in the participants' LDL-C was to be evaluated and averaged across treatment Week 12 and Week 16.	Baseline and Weeks 12 to 16	No
Secondary	Percent Change From Baseline in the Ratio of LDL-C to High-Desity Lipoprotein Cholesterol (HDL-C) at Week 16	The percentage from baseline in the participants' ration of LDL-C to HDL-C was to be evaluated at study Week 16.	Baseline and Week 16	No
Secondary	Percent Change From Baseline in HDL-C at Week 16	The percentage change from baseline in the participants' HDL-C was to be evaluated at study Week 16.	Baseline and Week 16	No
Secondary	Percent Change From Baseline in Triglycerides (TG) at Week 16	The percentage change from baseline in participants' TG level was to be evaluated at study Week 16.	Baseline and Week 16	No
Secondary	Percent Change From Baseline in Non-HDL-C at Week 16	The percentage change from baseline in participants' non-HDL-C was to be calculated at study Week 16.	Baseline and Week 16	No
Secondary	Percent Change From Baseline in the Ratio of Total Cholesterol (TC) to HDL-C at Week 16	The percentage change from baseline in the ratio of TC to HDL-C was to be evaluated at study Week 16.	Baseline and Week 16	No
Secondary	Percent Change From Baseline in Lipoprotein(a) (LP[a]) at Week 16	The pecentage change from baseline in participants LP(a) was to be evaluated at study Week 16.	Baseline and Week 16	No
Secondary	Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16	The percentage change from baseline in participants' Apo B was to be evaluated at study Week 16.	Baseline and Week 16	No
Secondary	Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 16	The percentage change from baseline in participants' Apo A-I was to be evaluated at study Week 16.	Baseline and Week 16	No